The oral solution in the prefilled ENFit syringe offers a safer alternative for adult subarachnoid haemorrhage patients.
Azurity Pharmaceuticals’ Nymalize (nimodipine) oral solution in a 30mg/5ml prefilled ENFit syringe has received US Food and Drug Administration (FDA) approval. Stainless Steel Continuous Syringe
The ready-to-use prefilled syringe offers an additional layer of security for both patients and healthcare professionals when administering medication.
The gold standard of business intelligence.
The oral solution in the prefilled ENFit syringe offers an effective alternative for adult subarachnoid haemorrhage patients who are unable to swallow capsules.
The adoption of ENFit connectors, which are recommended by the FDA, is said to be on the rise, with around 60% of acute care facilities in the US making the switch from traditional nasogastric tubing.
Nymalize improves neurological outcomes by reducing the incidence and severity of ischemic deficits in adults with subarachnoid haemorrhage from ruptured intracranial berry aneurysms.
It is suitable for patients across a range of post-ictus neurological conditions, classified from Hunt and Hess Grades I to V.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
The Nymalize prefilled ENFit syringes (30 mg/5 ml), along with prefilled oral syringes (30 mg/5 ml and 60 mg/10 ml) and 8 oz (237 ml) bottles will soon be available for order through pharmaceutical wholesalers.
Azurity Pharmaceuticals CEO Richard Blackburn stated: “Patients are our priority, and our purpose is to bring them new formulations and delivery systems that help them benefit from established medicines.
“Delivering Nymalize with ENFit syringes may offer patients and healthcare professionals a more secure, reliable drug administration through standardisation.”
In September 2022, the FDA granted approval for Azurity’s Konvomep (omeprazole and sodium bicarbonate for oral suspension) to treat active benign gastric ulcers.
The gold standard of business intelligence.
Give your business an edge with our leading industry insights.
Give your business an edge with our leading industry insights.
Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
View all newsletters from across the GlobalData Media network.
Veterinary Injection Gun The leading site for news and procurement in the pharmaceutical industry